Phase 1 Study of Anti-Glycation Agent GLY-230 in Healthy Subjects
This study has been completed.
Sponsor:
Glycadia
Information provided by:
Glycadia
ClinicalTrials.gov Identifier:
NCT00544921
First received: October 15, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes |
Drug: GLY-230 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Phase 1 Study of Anti-Glycation Agent GLY-230 |
Resource links provided by NLM:
Further study details as provided by Glycadia:
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Men age 18-55
- Negative drug screen
- Normal EKG, clinical chemistries, CBC, urinalysis, and
- Give written informed consent
Exclusion Criteria:
- Active concomitant serious medical or surgical disease,
- Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00544921 History of Changes |
| Other Study ID Numbers: | GLY-001 |
| Study First Received: | October 15, 2007 |
| Last Updated: | October 15, 2007 |
| Health Authority: | United States: Food and Drug Administration |
ClinicalTrials.gov processed this record on October 17, 2012
